Related Experiment Video
Updated: Jun 10, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Glucagon-like peptide 1--a cardiologic dimension
Marek Treiman1, Mikkel Elvekjaer, Thomas Engstrøm
1Department of Biomedical Sciences and The Danish National Foundation Research Center for Heart Arrhythmia, University of Copenhagen, Copenhagen, Denmark. m.treiman@mfi.ku.dk
Abstract:
Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon
Dipeptidyl Peptidase 4 Inhibitors
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are co-secreted in...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Hypoglycemia
